P03-25 Risperidone long-acting injectable in stable patients with schizophrenia or related disorders switched from oral olanzapine
β Scribed by Rosa, F.; Thomas, P.; Schreiner, A.; Sherif, T.
- Book ID
- 122416587
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- French
- Weight
- 45 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0924-9338
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Objective An international, nonβrandomised study evaluated efficacy and safety of risperidone longβacting injectable (RLAI) compared to previous treatment. To investigate generisability of the European data set to the UK subset safety and switching data are reported here. ## Method
## Abstract ## Objective This international, nonβrandomised study evaluated maintained efficacy and safety of Risperidone LongβActing Injectable (RLAI) compared to previous medications. To investigate the possible effect of differences in national health care systems across Europe, the UK subset e
## Abstract ## Objective To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to longβacting injectable risperidone (LAIR) in patients with schizophrenia. ## Methods Thirtyβsix patients with schizophrenia treated with oral